Metabolomics and proteomics
Untargeted liquid chromatography–mass spectrometry (LC-MS) metabolomics. We have performed untargeted liquid chromatography–mass spectrometry (LC-MS) analyses to characterize more than 1,000 serum metabolites and molecular features, including fatty acids, fatty amides, acylcarnitines, phospholipids, sterols, amino acids, gut microbiota-derived metabolites, purine metabolites, and xenobiotics.
Nuclear magnetic resonance (NMR) metabolomics. More than 220 serum metabolic measures have been quantified using the high-throughput Nightingale nuclear magnetic resonance (NMR) platform. These include lipids, lipoproteins, apolipoproteins, fatty acids, amino acids, glycoprotein acetyls, and creatinine.
Targeted liquid chromatography–mass spectrometry (LC-MS) metabolomics. To complement these measurements, we plan to perform targeted plasma metabolomic profiling using the Biocrates MxP Quant 1000 platform, enabling standardized quantitative analysis of a broad range of metabolites involved in glucose, lipid, and other metabolic pathways.
Proteomics. We also plan to analyze more than 5,000 plasma proteins using the high-throughput Olink Explore HT platform. This technology combines proximity extension assays with next-generation sequencing to provide extensive profiles of circulating proteins and molecular pathways associated with health and disease.
Integrating metabolomic and proteomic data with genetic, lifestyle, whole-body adiposity, abdominal subcutaneous and visceral fat and liver fat imaging, and clinical measurements will enable investigation of molecular pathways associated with insulin resistance, other disturbances in glucose and lipid metabolism, liver fat accumulation, and other chronic disease risk factors across the life course.
